Peter Attia MD409 ‒ Inside modern drug development: the science, economics, and regulatory hurdles
At a glance
WHAT IT’S REALLY ABOUT
How drugs are built: bimagrumab, trials, patents, and prevention frontiers
- Lloyd Klickstein describes a patient-need-driven approach to translational medicine, emphasizing that the hardest innovations involve creating new indications, endpoints, and regulatory pathways rather than incremental “me-too” improvements.
- The episode breaks down drug modalities (small molecules, biologics, gene/cell therapies, devices) and explains how binding affinity, developability, and patient practicality steer the choice of therapeutic format.
- A detailed case study follows bimagrumab from target rationale through antibody screening, animal proof-of-concept, IND-enabling work, GMP manufacturing, and first-in-human study design, highlighting cost, risk management, and why late-stage failures are so damaging.
- Bimagrumab increased human muscle mass modestly and inconsistently improved function, but unexpectedly reduced fat mass and improved glycemic control, leading to renewed interest in obesity/metabolic disease when paired with incretin therapies.
- The BELIEVE trial’s combination approach delivered very large fat loss but surfaced an LDL increase, and Klickstein closes by arguing the next frontier is true medical prevention, including a new pharmacologic strategy for cancer prevention inspired by drugs that inadvertently increase cancer risk.
IDEAS WORTH REMEMBERING
5 ideasDrug discovery often starts with unmet clinical need—not a molecule.
Klickstein describes a patient-need-first workflow: enumerate unmet indications, prioritize those with large societal impact, then build scientific, clinical, and regulatory paths in parallel. He contrasts incremental improvements (lower risk, clearer path) with “new indication creation,” which requires building measurement tools, awareness, and endpoints from scratch.
Modality selection is constrained by physics, not just preference.
He outlines major therapy “formats” (small molecules/chemicals; biologics like antibodies/peptides/soluble receptors; gene and cell therapies; devices) and notes format choice depends on biology, feasibility, patient practicality, and company capabilities. For high-affinity ligand–receptor systems (very “sticky” binding), antibodies may be required because small molecules often can’t compete at picomolar–nanomolar affinities.
The economics of innovation are dominated by time-limited exclusivity and IP strategy.
Klickstein explains patents as a time-limited monopoly (generally 20 years from filing), yielding roughly 10–15 years of post-launch exclusivity after development time. Companies may build dense “patent thickets” (formulation, device, dosing, method-of-use, manufacturing) to extend protection; trade secrets can also matter when manufacturing complexity is hard to replicate (e.g., historical examples like Armour Thyroid, Acthar).
If you can’t measure an outcome well, you can’t build a drug program around it.
A major barrier to sarcopenia/falls drug development is defining measurable, reliable endpoints. Klickstein recounts a failed attempt to objectively measure falls using wearable accelerometers in nursing home residents (poor sensitivity/specificity), which effectively halted that program—illustrating how endpoint feasibility can determine whether an indication is developable.
Bimagrumab reliably increases muscle mass, but function is harder to move clinically.
Bimagrumab blocks activin receptor type II signaling, inhibiting the inhibitory pathway (myostatin + activins) that limits muscle growth; in rodents it produced dramatic hypertrophy and functional gains, but in humans muscle mass increases were modest (~4–8%). Across many Novartis studies, muscle size gains did not translate into large functional improvements without other interventions (e.g., resistance training and adequate protein).
WORDS WORTH SAVING
5 quotesA patent is essentially a monopoly on being able to make, use, and sell the drug, uh, in exchange for telling everybody how to do it.
— Lloyd B. Klickstein
If you have, say, 20 risks you're taking in a drug development program... and all of them have, have maybe a 90% chance of success, you multiply all that out 10 or 20 times, it's zero.
— Lloyd B. Klickstein
Actually, that's probably not true. The worst outcome is succeeding in phase three and failing commercially.
— Lloyd B. Klickstein
We had to stop our whole program for making drugs to prevent falls because we couldn't measure them.
— Lloyd B. Klickstein
Conceptually, it's no different than going and, and, than a drug user going and buying some opioid from a street corner drug dealer. You have no idea what's in that.
— Lloyd B. Klickstein
High quality AI-generated summary created from speaker-labeled transcript.
